Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.

Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2020 Oct 02;: Authors: Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust JA, Kyle R, Ketterling RP, Bergsagel PL, Greipp PT, Kumar SK Abstract BACKGROUND: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma (MM), but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in newly diagnosed MM. PATIENTS AND METHODS: This is a retrospective study including 1342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, and who had cytogenetic testing by fluorescence in-situ hybridization at diagnosis, including MYC testing using the break apart FISH probe (8q24.1). RESULTS: A rearrangement involving MYC was found in 8% of patients, and was associated with elevated β2-microglobulin, ≥50% bone marrow plasma cells, IgA MM, and the co-occurrence of trisomies. There were no differences in overall response rates between patients with and without MYC rearrangement when induction chemotherapy was proteasome inhibitor (PI)-based, immunomodulatory drug (IMiD)-based or PI+IMiD-based. Overall survival was shorter in patients w...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Related Links:

ConclusionMALAT1 is involved in HR pathway by protecting BRCA1 and targeting MALAT1 induces DNA damages in NSCLC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
There is persistent racial disparities in survival among patients with Diffuse Large B Cell Lymphoma. We conducted a cohort study of 181 patients for 10 years in a single community-based inner-city cancer center. Blacks had decreased overall survival compared to non-Blacks even after excluding patients with HIV and who did not receive chemotherapy. R-IPI score alone could not predict worse outcomes and increased mortality in Blacks with DLBCL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Colon perforations are rare in MM and here we report characteristics and clinical outcomes of 30 patients that were treated at Mayo Clinic. We believe that steroids are the precipitating factor. AbstractGastrointestinal complications of multiple myeloma (MM) treatment are common and include nausea, constipation, and diarrhea. However, acute gastrointestinal events like perforations are rare. We aimed to describe the characteristics and outcomes of patients with MM that had colonic perforations during their treatment. This is a retrospective study that included patients from all three Mayo Clinic sites who had MM and develo...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This article has been retracted. Please see the retraction notice for more detail:
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
AbstractMultiple myeloma (MM) is diagnosed and monitored by correlating panel of test results including serum Protein electrophoresis (SPE), Immunofixation electrophoresis (IFE), serum Free Light chain (sFLC) measurements. This audit is aimed to evaluate the prevalence of non-correlation and discrepancies amongst the three investigations (SPE/IFE/sFLC) for assessment of MM. 106 MM patients were reviewed over 16  months in a tertiary cancer care center by the availability of 3 serum test results (SPE/IFE/sFLC). Patients were divided into 2 groups: group1, newly diagnosed MM patients who were yet to receive myeloma spec...
Source: Indian Journal of Clinical Biochemistry - Category: Biochemistry Source Type: research
CONCLUSIONS: LenMT dose correlated with efficacy and toxicity. High rates of dose reductions during CT argue against a high starting dose. However, continuous up- and down-titration for each patient to the current maximum tolerated dose is prudent. PMID: 32817078 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Authors: Roth P, Mason WP, Richardson PG, Weller M Abstract INTRODUCTION: Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy. Novel therapeutic options are therefore urgently needed; however, there have been various drug failures in late-stage clinical development. The proteasome represents a key target for anti-cancer therapy as successfully shown in multiple myeloma and other hematologic malignancies. AREAS COVERED: This review article summarizes the preclinical and clinical development of proteasome inhibitors in ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Conditions:   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   HDT-AHCT Intervention:   Drug: Romiplostim Sponsors:   Memorial Sloan Kettering Cancer Center;   Amgen Recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSIONS: The ability of the rotavirus isolates Wt1-5, WWM, TRUYO, ECwt-O, and WTEW to infect and cause cell death of Sp2/0-Ag14 cells through mechanisms that are compatible with virus-induced apoptosis makes them potential candidates as oncolytic agents. PMID: 32673463 [PubMed - in process]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
Conclusions: Patients with mm could benefit from a consistent tst testing policy coupled with subsequent ltbi therapy. However, universal testing might not be required. A targeted program combining evaluation of host risk factors, imaging findings, and screening tests might optimize ltbi diagnosis and management, and thus be effective in preventing the development of active tb in at-risk patients with mm. PMID: 32669929 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Fish | Myeloma | Study